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Abstract
Background
Current research on the relationship between phytoestrogens and mortality has been inconclusive. We explored the relationship between genistein, a phytoestrogen, and mortality in a
large cohort representative of the United States population.

Methods
Data were analyzed from the National Health and Nutrition Examination Survey (NHANES)
from 1999–2010. Normalized urinary genistein (nUG) was analyzed as a log-transformed
continuous variable and in quartiles. Mortality data were obtained from the National Death
Index and matched to the NHANES participants. Survival analyses were conducted using
the Kaplan-Meier analysis. Cox proportional hazard models were constructed for all-cause
and cause-specific mortality without and with adjustment for potential confounding
variables.

Results
Of 11,497 participants, 944 died during the 64,443 person-years follow-up. The all-cause
mortality rate was significantly lower in the lowest quartile compared to the highest quartile
(incidence rate ratio = 2.14, 95%CI = 1.76 to 2.60). Compared to the lowest quartile, the
highest quartile had significantly higher adjusted all-cause (HR = 1.57, 95%CI = 1.23 to
2.00), cardiovascular (HR = 1.67, 95%CI = 1.04 to 2.68), and other-cause (HR = 1.85, 95%
CI = 1.33 to 2.57) mortality.

Conclusion
We found that high urinary genistein levels were associated with increased risk of all-cause,
cardiovascular, and other-cause mortality. This is contrary to popular opinion on the health
benefits of genistein and needs further research.
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Introduction
Phytoestrogens are plant-based chemical compounds with structural similarities to female sex
hormones such as 17-β-estradiol and diethylstilbestrol [1]. The wide range of naturally-occurring
phytoestrogens can be sub-classified into several groups: isoflavones, prenylflavonoids, coumestans, and lignans. The most common phytoestrogens are isoflavones found in a variety of fruits
and vegetables, particularly soy products, legumes, and flax [2]. One of the major isoflavones that
is commonly consumed by humans is genistein, which is typically found in soy products [1].
Several studies have suggested that phytoestrogens are associated with a lower risk of allcause mortality [3,4], cardiovascular disease mortality [3], and cancer mortality [5–8]. Other
studies have found no benefit of phytoestrogen intake on all-cause, cardiovascular, or cancer
mortality [9–14]. Interestingly, some studies have found an increased mortality risk with phytoestrogen intake [15,16]. The conflicting results from these studies may, at least partly, be due
to participant self-reports of dietary phytoestrogen intake—a measure associated with significant error in the measurement of actual phytoestrogen intake [17].
Urinary excretion of phytoestrogen is an objective measure which is independent of recall
bias associated with self-reports of dietary intake. Several studies have found that urine isoflavone concentrations were significantly correlated to dietary intake [18–20]. Given the conflicting results of prior studies, we decided to explore the relationship between genistein, a
phytoestrogen, and all-cause, cardiovascular, cancer, and other-cause mortality in a large
cohort representative of the United States population using urinary genistein levels as a marker
of dietary intake.

Methods
We used the continuous National Health and Nutrition Examination Survey (NHANES), an
ongoing cross-sectional, complex, multistage, stratified, clustered sampling design survey representative of the civilian, noninstitutionalized population of the United States. NHANES was
approved by the Centers for Disease Control and Prevention’s Institutional Review Board, and
all participants provided written informed consent. Detailed descriptions of survey methods
and procedures are available on the NHANES website [21]. Participants from six survey cycles
(1999–2010) who were older than 20 years were included in the study. Mortality data were
obtained from the National Death Index (NDI), which is a centralized database of death records. The National Center for Health Statistics linked surveys to death records from the NDI
by matching identifying information such as Social Security number. We categorized cause of
deaths into all-cause deaths, cardiovascular deaths, deaths due to cancer, and deaths due to
other causes (other-cause mortality).

Study variables
Race, sex, and age were self-reported, and all ages greater than 85 years were recorded as 85.
Young was defined as age 45 years or younger, middle-age was defined as ages younger than
65 years and older than 45 years, and elderly was defined as age 65 years and older. Subjects
were categorized as active smokers, ever-smokers who had smoked at least 100 cigarettes in
their lifetime, or nonsmokers who had never smoked. The body mass index (BMI) was calculated by dividing the weight in kilograms by the height in meters squared, with height and
weight obtained by trained body measurement health technicians. Hypertension was defined
as carrying a diagnosis of hypertension, use of antihypertensive medications, or having an
average of three blood pressure measurements greater than 140/90. Blood pressure was measured by certified blood pressure examiners who averaged three to four manual blood pressure
measurements. Diabetes was categorized as participants who had ever been diagnosed with
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diabetes, had a hemoglobin A1C greater than 7.0%, or were on medication for diabetes. Hemoglobin A1C was measured on the fully automated glycohemoglobin analyzer. C-reactive protein (CRP) was measured from serum samples by latex-enhanced nephelometry. Cholesterol
was measured in serum via the Roche Modular P chemistry analyzer (Roche Diagnostics, Indianapolis, Indiana, USA) using an enzymatic process. Serum creatinine was measured using the
Jaffe rate method (kinetic alkaline picrate). Glomerular filtration rate (GFR) was estimated
using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation [22]. Urinary creatinine was measured using the Roche/Hitachi Modular P Chemistry Analyzer (Roche
Diagnostics, Indianapolis, Indiana, USA) at the University of Minnesota. Glucuronidated
genistein in human urine samples was deconjugated enzymatically, separated from other urine
components by reversed phase high performance liquid chromatography, detected by atmospheric pressure photoionization-tandem mass spectrometry, and quantified by isotope dilution. Urinary genistein concentrations were normalized for urine dilution or concentration
using urinary creatinine (urinary genistein concentration in ng/mL divided by urinary creatinine concentration in mg/dL).

Statistical methods
Mean (SD), median (interquartile range), or frequencies were used as descriptive statistics as
appropriate. We conducted all analyses while taking into account the complex survey sampling
design of the NHANES. Survey weights were generated from the six 2-year cycles for the complete dataset so that the results are representative of the United States population. Survival estimates were obtained using Kaplan-Meier method. Cox proportional hazard models were
constructed with and without adjustment for sex, race, hypertension, diabetes mellitus, and
smoking (categorical variables); and age, BMI, serum CRP, cholesterol, and estimated GFR
(continuous variables). We conducted all-cause mortality and cause-specific mortality analyses
as outcomes. We log-transformed normalized urinary genistein levels due to distribution
skewness and analyzed it as a continuous variable. To confirm that the observed relationship is
independent of the statistical assumption about the distribution of normalized urinary genistein (nUG), we also examined adjusted and unadjusted models with quartiles of nUG. Test for
trend was performed by entering the categorical variable of quartiles as continuous variable in
the model. For sensitivity analysis, we used competing-risk models to confirm that the relationship we found was independent of the assumptions of the hazard distributions. All analyses were conducted using Stata 14.0 (College Station, Texas, USA).

Results
Descriptive results
Of the 11,497 participants in the study, 52% were female, 23% were elderly, 49% were white,
36% had hypertension, 12% had diabetes, and 21% were current smokers (Table 1). The mean
(SD) age was 49.2 (18.4) years, BMI was 28.8 (6.6) kg/m2, and GFR was 93.7 (24.2) ml/min.
The median (IQR) serum CRP was 0.21 (0.42) mg/dL and nUG was 0.24 (0.73) ng/mL/mg creatinine. During the mean follow-up of 5.6 (3.6) years and total follow-up of 64,443 personyears, there were 944 deaths—231 deaths due to cardiovascular disease, 239 deaths due to
malignancy, and 474 deaths due to other causes.

All-cause mortality
The mortality rate was 9.1 (95%CI = 7.8 to 10.7) deaths per 1000 person-years in the lowest
quartile compared to 19.2 (95%CI = 17.1 to 21.5) deaths per 1000 person-years in the highest
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Table 1. Population variables by mortality status.
Variable

Mortality Status
Deceased (N = 944)

P-value

Alive
(N = 10,553)

Total
(N = 11,497)

Normalized urinary genistein (ng/mL/mg creatinine)�

0.33 (1.13)

0.22 (0.71)

0.23 (0.73)

<0.001

Age (years)

70.9 (13.79)

47.2 (17.57)

49.2 (18.48)

<0.001

Young

63 (6.67)

5295 (50.18)

5358

<0.001

Middle Age

195 (20.66)

3263 (30.92)

3458

<0.001

Elderly

686 (72.67)

1995 (18.90)

2681

<0.001

BMI (kg/m2)

27.7 (5.9)

28.9 (6.6)

28.8

<0.001

69.2 (23.5)

95.8 (23.1)

93.7 (24.2)

<0.001

CRP (mg/dL)

0.32 (0.67)

0.20 (0.40)

0.21 (0.3)

<0.001

Cholesterol (mg/dL)

200.6 (43.2)

198.5 (42.3)

198.7 (42.4)

0.16

Creatinine (mg/dL)

1.10 (0.62)

0.87 (0.29)

0.89 (0.34)

<0.001

Female

418 (44.28)

5608 (53.14)

6026

<0.001

Hypertension

614 (65.04)

3518 (33.34)

4132

<0.001

Diabetes

220 (23.31)

1170 (11.09)

1390

<0.001

Black

173 (18.33)

2021 (19.15)

2194

<0.001

Hispanic

190 (20.13)

3003 (28.46)

3193

<0.001

White

561 (59.43)

5055 (47.90)

5616

<0.001

Other race

20 (2.12)

474 (4.49)

494

<0.001

Current smoker

207 (21.93)

2223 (21.08)

2430

<0.001

Ever smoker

368 (38.98)

2544 (24.13)

2912

<0.001

Nonsmoker

369 (39.09)

5777 (54.79)

6146

<0.001

Estimated GFR (mL/min/1.73 m2)
�

Race

Tobacco Use

Data are presented as mean (SD) for continuous variables and N (%) for categorical variables. P-values were generated by X2 test or two-sample t test as indicated.
�

Variable presented as median (interquartile range). P-values were generated by the Kruskal-Wallis test.

https://doi.org/10.1371/journal.pone.0211368.t001

quartile (incidence rate ratio = 2.14, 95%CI = 1.76 to 2.60, p < 0.001) (Fig 1). Using the
Kaplan-Meier analysis, survival was statistically significantly higher (p< 0.0001) in the lowest
quartile of nUG than in the highest quartile–there were 153 deaths in the lowest quartile and
298 deaths in the highest quartile during the study time span (Fig 2).
Using the Cox proportional hazards model, we found a statistically significant direct relationship between nUG levels and risk of mortality that was robust when adjusting for confounders (Fig 3). In adjusted models, for every log increase in nUG, there was a 9% increase in
risk of mortality (HR = 1.09, 95%CI = 1.04 to 1.15, p = 0.001), and individuals in the highest
quartile of nUG had a 57% higher risk of mortality compared to individuals in the lowest quartile (HR = 1.57, 95%CI = 1.23 to 2.00, p < 0.0001). Furthermore, the trend for increasing mortality was significant without (HR = 1.21, 95%CI = 1.13 to 1.30, p < 0.001) and with
adjustment (HR = 1.14, 95%CI = 1.0 to 1.24, p = 0.001) for potential confounders.

Cause-specific mortality
Using the Cox proportional hazards model, for every log increase of nUG, there was a 14%
increase in risk of cardiovascular disease mortality (HR = 1.14, 95%CI = 1.05 to 1.24,
p = 0.002) (Fig 3). However, after adjusting for potential confounders, the relationship between
nUG and the risk for cardiovascular disease mortality did not reach statistical significance
(HR = 1.11, 95%CI = 0.99 to 1.24, p = 0.06). When analyzing data using quartiles of nUG,
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Fig 1. Mortality incidence rates (per 1000 person-years) for each quartile of normalized urinary genistein levels.
The incidence rate of death was significantly lower (p < 0.001) in the first quartile of normalized urinary genistein
(nUG) compared to the fourth quartile of nUG. The mortality incidence rate was 9.1 deaths per 1000 person-years (CI
7.8 to 10.7) in the first quartile versus 19.2 deaths per 1000 person years (CI 17.1 to 21.5) in the fourth quartile.
https://doi.org/10.1371/journal.pone.0211368.g001

however, the relationship was statistically significant in unadjusted and adjusted analyses. In
adjusted models, individuals in the highest quartile of nUG had a 67% higher risk of cardiovascular disease mortality compared to individuals in the lowest quartile (HR = 1.67, 95%
CI = 1.04 to 2.68, p = 0.03).
For cancer mortality (Fig 3), there was no statistically significant relationship with nUG
without adjustment (HR = 1.05, 95%CI = 0.96 to 1.16, p = 0.28) and with adjustment
(HR = 1.01, 95%CI = 0.89 to 1.14, p = 0.87) for potential confounders. Similarly, comparing
the lowest to the highest quartile of nUG, there was no statistically significant relationship in
unadjusted (HR = 1.33, 95%CI = 0.73 to 2.42, p = 0.35) or adjusted models (HR = 1.01, 95%
CI = 0.51 to 2.00, p = 0.99).

PLOS ONE | https://doi.org/10.1371/journal.pone.0211368 January 25, 2019

5 / 12

Urinary genistein levels and mortality

Fig 2. Kaplan-Meier curve comparing survival rates of the lowest and highest quartiles of normalized urinary genistein.
There was a statistically significant higher survival rate among individuals in the first quartile of normalized urinary
genistein (nUG) compared to those in the fourth quartile of nUG (p < 00001).
https://doi.org/10.1371/journal.pone.0211368.g002

Finally, there was a statistically significant direct relationship between nUG and other-cause
mortality in unadjusted and adjusted analyses (Fig 3). Using adjusted data, every log increase in
nUG was associated with a 13% increase in risk of other-cause mortality (HR = 1.13, 95%
CI = 1.05 to 1.23, p = 0.002). Similarly, we found a significantly higher risk of other-cause mortality in participants in the highest than in the lowest quartile in unadjusted (HR = 2.21, 95%
CI = 1.59 to 3.06, p < 0.001) and adjusted models (HR = 1.85, 95%CI = 1.33 to 2.57, p < 0.0001).

Sensitivity analysis
Competing risk models for cardiovascular, cancer, and other-cause mortality found results
similar to the Cox proportional hazards model. For cardiovascular mortality, the association
seen in unadjusted analysis (HR = 1.15, 95%CI = 1.08 to 1.24, p < 0.0001) disappeared after
adjusting for potential confounders (HR = 1.08, 95%CI = 1.00 to 1.18, p = 0.06). As compared
to the lowest quartile, participants in the highest quartile had higher cardiovascular mortality
risk in unadjusted (HR = 2.4, 95%CI = 1.60 to 3.60, p < 0.001) and adjusted analyses (HR =
1.79, 95%CI = 1.15 to 2.79, p = 0.01). For cancer mortality, unadjusted and adjusted results
remained non-significant with nUG as continuous variable or in quartiles. Similar to the Cox
proportional hazards models, other-cause mortality was significantly associated with nUG. In
adjusted models, every log increase in nUG was associated with 13% higher mortality risk
(HR = 1.13, 95%CI = 1.06 to 1.20, p < 0.0001), and individuals in the highest quartile had a
70% higher risk of other-cause mortality than those in the lowest quartile (HR = 1.70, 95%
CI = 1.27 to 2.27, p < 0.0001).

PLOS ONE | https://doi.org/10.1371/journal.pone.0211368 January 25, 2019

6 / 12

Urinary genistein levels and mortality

PLOS ONE | https://doi.org/10.1371/journal.pone.0211368 January 25, 2019

7 / 12

Urinary genistein levels and mortality

Fig 3. Adjusted and unadjusted all-cause and cause-specific mortality. Using Cox proportional hazard models,
there was a statistically significant increase in all-cause mortality with higher levels of nUG in both adjusted and
unadjusted data. There was a statistically significant increase in cardiovascular mortality when examining quartiles of
nUG (both adjusted and unadjusted models) but not when nUG was examined as a continuous variable. There was no
statistically significant relationship between nUG and cancer mortality in either adjusted or unadjusted data. Finally,
there was a statistically significant increase in other-cause mortality with higher levels of nUG in both adjusted and
unadjusted data.
https://doi.org/10.1371/journal.pone.0211368.g003

Discussion
In this study, we report an association between higher urinary genistein levels and increased
risk of all-cause and other-cause mortality that was independent of potential confounding variables and robust to distributional assumptions of the nUG. We further found that nUG has no
association with cancer mortality. The association between nUG and cardiovascular mortality
was complex; the association was independent of potential confounding variables when nUG
was examined in quartiles but not when examined as a log-transformed continuous variable.
Our results were robust to statistical modeling assumptions and remained unchanged in sensitivity analyses using competing-risk models.
Genistein is quickly absorbed after oral intake due to its small molecular weight and lipophilic properties. It has a low oral bioavailability due to its high rate of metabolism in the intestine and liver. Remaining genistein metabolites move to the liver via the portal vein and
undergoes further metabolism. Genistein is mostly distributed in the gastrointestinal tract and
liver due to its hydrophilic nature preventing its diffusion and accumulation in other tissues.
Additionally, genistein undergoes enterohepatic recycling via highly active efflux transporters
in the intestine which excrete genistein back into the lumen of the gastrointestinal tract where it
is metabolized by gut flora and reabsorbed by the enterocytes. However, genistein metabolites
can also be found in the urine in moderate amounts which suggests that urinary excretion is
one of the major elimination pathways of genistein [23]. Individual differences in enzymatic
activity within the intestine and liver as well as gut microbiome may result in differences in how
genistein is metabolized which may in turn affect the amount of genistein excreted in the urine.
Several molecular pathways may be responsible for the observed findings between high urinary genistein levels and increased mortality. Genistein may have a potentially deleterious
effect on the immune system as it decreases thymic size in ovariectomized female and male
mice in a dose-dependent manner. The effect on immune system may be independent of its
interaction with estrogen receptor as an estrogen receptor blocker did not completely block
genistein’s effect on thymic size [24]. Genistein’s effect on the thymus may lead to splenic and
total body lymphocytopenia through inducing apoptosis of CD4+/CD8+ and CD4+/CD8- thymocytes [24]. Furthermore, genistein has also been shown to decrease delayed hypersensitivity
responses [25]. Thus, genistein may have significant implications for humoral and cellular
immunity. Genistein may also cause genotoxicity by increasing DNA breakage through its
effect on the topoisomerase II enzyme [26,27]. In fact, genistein genotoxicity has been
observed in a wide variety of cell lines including Chinese hamster lung fibroblasts, L5178Y
mouse lymphoma cells, and human colon and lymphocyte cell lines [28–32].
Few epidemiological studies have examined the relationship between all-cause or causespecific mortality and phytoestrogens in general, or genistein specifically, with conflicting
results. A systematic review of phytoestrogens’ association with all-cause mortality included
eight studies that collectively enrolled 97,118 individuals and identified 12,228 deaths during a
median follow-up of 12.8 years [33]. The systematic review found a pooled relative risk of 0.86
(95%CI = 0.73 to 1.00) although there was significant heterogeneity between the studies (I2 =
68%; P = 0.003). For the association of phytoestrogen intake and cardiovascular mortality, this
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systematic review found 13 studies including 338,541 participants and 7774 deaths and
reported a pooled relative risk of 0.86 (95%CI = 0.75 to 0.98) [33]. Of note, studies included in
this review measured phytoestrogen intake using self-report through various methods [33].
Another systematic review identified two studies that measured phytoestrogen intake using
more objective measures such as spot urine or serum levels and examined the association
between phytoestrogen intake and all-cause mortality. These studies had conflicting results for
phytoestrogens as a group but found no association of genistein with all-cause mortality;
results from these two studies were not pooled [34].
Reger, et al performed a similar study in 2014 reviewing NHANES data from 1999–2004.
They found that the median urinary concentrations of total isoflavones were higher in study
participants who died from cardiovascular disease suggesting an increased risk of cardiovascular mortality is associated with higher concentration of urinary isoflavones [16]. Their study
examined multiple isoflavones as a group, including genistein, daidzein, equol, and O-desmethylangolensin, and although their findings were significant in isoflavones as a group and
in daidzein individually, they did not report significant findings in urinary genistein levels.
This subtle difference in their findings from our study may be attributed to a lower sample
size. While this study also examined NHANES data, they used data only from 1999 through
2004 while our study examined NHANES data from 1999 through 2010. We therefore had a
much larger study population (11,753 in our study, compared to 5,179 in their study) and longer follow-up time to allow more time for change. Additionally, we adjusted for more known
risk factors associated with cardiovascular disease, including diabetes mellitus and hypertension, which was not included in Reger, et al’s analysis.
Most studies examining the relationship between phytoestrogens and mortality were conducted in breast cancer patients. Several of these studies showed an inverse relationship
between phytoestrogens and mortality from breast cancer [5–7]. In addition, all-cause mortality was found to be lower in women with ER-negative/PR-negative breast cancer and high
intake of isoflavones in one study enrolling a diverse cohort [8]. In contrast, several other studies found no association between phytoestrogen intake and mortality [6,15,35]. When phytoestrogen intake was further categorized by the group of phytoestrogens in one study, only high
lignan intake was associated with lower risk of all-cause mortality in post-menopausal breast
cancer patients [15]. Consistent with most other studies noted above, these studies relied on
self-report by patients to quantify dietary phytoestrogens intake. Three studies that examined
serum levels of a phytoestrogen, enterolactone, found that high serum enterolactone levels
were associated with significant reduction in all-cause mortality and breast cancer-specific
mortality in breast cancer patients [36–38].
The conflicting results above may arise from the recall bias and measurement error that is
inherent in self-report methods of determining dietary intake. In addition, it is possible that
phytoestrogens may not have a specific group-effect on all-cause or cause-specific mortality
and each member of the phytoestrogen group needs to be examined separately. To this end,
we examined a more objective method of measurement thus eliminating recall bias and possibly reducing measurement error. Furthermore, we focused on an individual member of the
phytoestrogen group and determined the effect of genistein.
Our study has important clinical, public health, and research implications. Findings from
this study are contrary to the perceived benefits of phytoestrogens and soy-rich diets. Given
the observed association of an increase in mortality with increase in urinary genistein levels,
the safety of genistein needs to be examined before any clinical recommendation on its use in
practice. Soy-products are rich in genistein and are commonly used in various dietary supplements, suggesting a public health urgency for a better understanding. As the public continues
to focus on potential benefits of genistein and other phytoestrogens, the use of these substances
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in health supplements may continue to increase. Thus, there is a growing need for more
research examining the long-term effects and safety of genistein. Further research is needed to
identify which, if any, of the phytoestrogens promote or protect health. In addition, molecular
mechanisms through which genistein acts need to be explored further.
This study had several strengths and limitations. The main strengths of this study are the
use of a diverse large cohort representative of the United States population and the use of hard
endpoints (mortality). Additionally, in our analyses we accounted for competing events, i.e.
cause of mortality, that was not accounted for in the Kaplan-Meier and Cox proportional hazard models by performing a competing risk analysis, which confirmed our findings in the
other models. Urinary genistein has been positively correlated to dietary intake in previous
studies [18–20] and therefore could be considered an objective measure of dietary intake, but
individual differences in metabolism could potentially affect urinary genistein levels and therefore affect this correlation with dietary intake. Additionally, since this is an observational
study, we cannot determine if there is a causal relationship between genistein levels and mortality. Further, urinary genistein levels were measured at one time point only limiting our ability to assess changes in genistein intake.
In conclusion, we found an increased risk of all-cause mortality with higher levels of urinary genistein. The mechanisms by which genistein may increase mortality is uncertain and
warrants further study. Given the findings of this study, the long-term effects and safety of
genistein will need to be further investigated.
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